Document is current

Any future updates will be listed below

Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia

Crossref DOI link: https://doi.org/10.1007/s00277-015-2485-x

Published Online: 2015-09-04

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark